Document is current
Any future updates will be listed below
-
Authors
Yoshikawa, Fukumi
Kumashiro, Naoki
Shigiyama, Fumika
Miyagi, Masahiko
Ando, Yasuyo
Uchino, Hiroshi
Hirose, Takahisa https://orcid.org/0000-0001-6293-5010
-
Funding
Funding for this research was provided by:
JSPS KAKENHI (18K07481)
- License Information
-
More Information
Article History
Received: 17 March 2021
Accepted: 25 May 2021
First Online: 2 June 2021
Declarations
:
: T. Hirose received research funds from Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd.; and received lecture fees from Sanofi K.K., Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Company Limited, MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, Kowa Company, Limited, Kissei Pharmaceutical Co., Ltd. N. Kumashiro received research funds from Boehringer Ingelheim Pharmaceuticals, Inc., and lecture fees from Takeda Pharmaceutical Company Limited, Sanofi K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd. None of the funding agencies had any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
: The study was approved by the Medical Ethics Committee of Toho University Omori Medical Center (Approval no. #M19093; Approval date: August 29, 2019). This study was conducted according to the Declaration of Helsinki and current legal regulations in Japan.
: Prior to enrollment in the survey, all eligible participants were informed about this study in written form, and the answer to the questionnaire was considered consent to enrollment.
